| Literature DB >> 31002716 |
Daniel Mekonnen1,2, Awoke Derbie1,3, Andargachew Abeje4, Abebe Shumet5, Endalkachew Nibret2,6, Fantahun Biadglegne1, Abaineh Munshae2,6, Kidist Bobosha7, Liya Wassie7, Stefan Berg8, Abraham Aseffa7.
Abstract
INTRODUCTION: Tuberculous lymphadenitis is the most frequent form of extra-pulmonary TB (EPTB) and accounts for a considerable proportion of all EPTB cases. We conducted a systematic review of articles that described the epidemiological features of TBLN in Africa.Entities:
Mesh:
Year: 2019 PMID: 31002716 PMCID: PMC6474617 DOI: 10.1371/journal.pone.0215647
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1PRISMA flow diagram of literature selection, Africa, 2018.
Fig 2Geographic distribution and number of TBLN cases in Africa and Ethiopia, Africa, 1970–2015.
Reviewed articles and characteristics of TBLN cases, Africa, 1970–2015.
| Author, year (reference) | Study period | Design/ | Country | #TBLN pts | Sex | Age groups (Year) | HIV | |||
|---|---|---|---|---|---|---|---|---|---|---|
| M | F | ≤14 | 15–44 | ≥45 | Po/N/U | |||||
| Abdissa, 2014 [ | 2012 | CS/H | Ethiopia | 160 | 93 | 107 | 28 | 151 | 21 | 10/97/94 |
| Abebe, 2012 [ | 2009 | CS/C | Ethiopia | 87 | 4 | 12 | 0 | 12 | 4 | ND |
| Atomsa, 2014 [ | 2012 | CCS/H | Ethiopia | 48 | 18 | 30 | 0 | 47 | 1 | 0/48/0 |
| Berg, 2015 [ | 2006–2010 | CCS/C | Ethiopia | 456 | 138 | 167 | 120 | 148 | 21 | ND |
| Beyene, 2008 [ | 2005–2006 | CS/C | Ethiopia | 132 | 52 | 104 | 35 | 99 | 22 | 10/146/0 |
| Bezabih, 2002 [ | 2000 | CS/H | Ethiopia | 128 | 72 | 56 | 27 | 90 | 11 | ND |
| Bezabih, 2003 [ | 1999–2001 | CS/H | Ethiopia | 536 | 302 | 234 | 168 | 210 | 68 | ND |
| Biadglegne, 2013 [ | 2012 | CS/H | Ethiopia | 225 | 95 | 130 | 26 | 171 | 29 | ND |
| Fanosie, 2016 [ | 2015 | CS/H | Ethiopia | 87 | 74 | 67 | 29 | 76 | 36 | 24/12/0 |
| Kidane, 2002 [ | 2000–2001 | P/HC | Ethiopia | 40 | 24 | 16 | ND | ND | ND | 11/29/0 |
| Muluye, 2013 [ | 2003–2011 | R/Lab | Ethiopia | 2392 | 1098 | 1294 | 404 | 1689 | 299 | ND |
| Tadesse, 2017 [ | 2013–2015 | CS/HA | Ethiopia | 304 | 143 | 161 | 33 | 166 | 105 | 24/232/7 |
| Yassin, 2003 [ | 1998–2000 | CS/HC | Ethiopia | 107 | 51 | 56 | ND | ND | ND | 24/82/11 |
| Zewdie, 2017 [ | 2014 | CS/H | Ethiopia | 60 | 30 | 30 | 0 | 52 | 8 | ND |
| Bem, 1996 [ | 1981–1990 | R/H | Zambia | 238 | 247 | 216 | 53 | 182 | 115/11/342 | |
| Bem, 1997 [ | 1989–1990 | P/H | Zambia | 185 | 95 | 90 | ND | ND | ND | 157/28/0 |
| Marais, 2006 [ | 2003–2004 | P/HF | South Africa | 35 | 69 | 89 | 35 | 0 | 0 | ND |
| Khuzwayo, 2014 [ | 2007–2011 | R/H | South Africa | 302 | 196 | 162 | ND | ND | ND | 233/125/0 |
| Onuigbo, 1975 [ | 1970–1974 | R/ Lab | Nigeria | 100 | 57 | 43 | 22 | 60 | 16 | ND |
| Ukekwe, 2016 [ | 2000–2014 | R/H | Nigeria | 172 | 84 | 88 | 26 | 123 | 23 | 23/5/144 |
| Beogo, 2013 [ | 2001–2010 | R/H | Burkina Faso | 115 | 53 | 62 | 16 | 74 | 21 | 42/72/0 |
| Wamala, 2014 [ | 2010–2012 | CS/H | Uganda | 120 | 58 | 62 | ND | ND | ND | 75/39/7 |
| Blouin, 2014 [ | 2010–2013 | CS/HA | Djibouti | 8 | 5 | 3 | 8 | 0 | 0 | 0/7/1 |
| Viegas, 2015 [ | 2013–2014 | CS.H | Mozambique | 45 | 28 | 17 | 0 | 45 | 0 | 30/9/6 |
| Ageep, 2012 [ | 2008–2011 | R/Lab | Sudan | 182 | 84 | 98 | 24 | 126 | 42 | ND |
| Smaoui, 2015 [ | 2009–2013 | R/ HA | Tunisia | 181 | 65 | 116 | ND | ND | ND | 0/181/0 |
| Richer, 1992 [ | 1984–1988 | R/H | Tanzania | 263 | ND | ND | ND | ND | ND | ND |
| Boeree, 1998 [ | 1994–1995 | CS/H | Malawi | 38 | ND | ND | 0 | 30 | 8 | 32/6/0 |
| Total | 6746 | 3235 | 3510 | 1054 | 3551 | 735 | ||||
CS: Cross-sectional, H: Hospital, CCS: Comparative Cross-Sectional, HA: Hospital admitted patients, C: Community based study, P: Prospective study, HC: Health Center, HF: Health Facility, R: Retrospective/Registry review, ND: No data found, #LNTB pts: Number of Tuberculous lymphadenitis patients, M: Male, F: Female, Po: Positive, N: Negative, U: Unknown
Robbins-I risk of bias summary for the included articles, Africa, 1970–2015.
| Study, Year (Reference) | Overall quality score | Risk of bias judgement |
|---|---|---|
| Abdissa, 2014 [ | 4 | Moderate |
| Abebe,2012 [ | 7 | Low |
| Atomsa,2014 [ | 7 | Low |
| Berg,2015 [ | 7 | Low |
| Beyene, 2008 [ | 7 | Low |
| Bezabih, 2002 [ | 7 | Low |
| Bezabih, 2003 [ | 7 | Low |
| Biadglegne, 2013 [ | 7 | Low |
| Fanosie,2016 [ | 4 | Moderate |
| Kidane, 2002 [ | 7 | Low |
| Muluye, 2013 [ | 5 | moderate |
| Tadesse,2017 [ | 7 | Low |
| Yassin 2003 [ | 7 | Low |
| Zewdie, 2018 [ | 7 | Low |
| Bem, 1996 [ | 5 | Moderate |
| Bem,1997 [ | 7 | Low |
| Marais, 2006 [ | 4 | Moderate |
| Khuzwayo, 2014 [ | 4 | Moderate |
| Onuigbo,1975 [ | 7 | Low |
| Ukekwe, 2016 [ | 7 | Low |
| Beogo, 2013 [ | 4 | Moderate |
| Wamala, 2014 [ | 5 | Moderate |
| Blouin, 2014 [ | 5 | Moderate |
| Viegas, 2015 [ | 7 | Low |
| Ageep, 2012 [ | 7 | Low |
| Smaoui,2015 [ | 7 | Low |
| Richer,1992 [ | 5 | Moderate |
| Boeree,1998 [ | 3 | Critical |
Fig 3Pooled prevalence of TBLN types and features, Africa, 1970–2015.
Fig 7Prevalence of cardinal TB symptoms among TBLN cases, Africa, 1970–2015.
Fig 4Proportion of female and age group of 15–44 years among TBLN cases, Africa 1970–2015.
Fig 5Proportion of TBLN/HIV co-infection among TBLN cases, Africa 1970–2015.
Fig 6Prevalence of key exposure variables among TBLN cases, Africa, 1970–2015.
A summary of pooled prevalence to key variables among tuberculous lymphadenitis patients, Africa, 1970–2015.
| Variables | #articles | PP | 95%CI | I2% | QeE |
|---|---|---|---|---|---|
| Lymph node features | |||||
| Cervical | 17 | 0.77 | 0.66–0.89 | 99 | low |
| Matted | 6 | 0.67 | 0.37–0.96 | 99.3 | low |
| Mobile | 6 | 0.64 | 0.39–0.89 | 99 | low |
| Demographic and HIV profiles | |||||
| Female gender | 23 | 0.53 | 0.51–0.55 | 0 | low |
| 15–44 years of age | 18 | 0.68 | 0.53–0.83 | 99.5 | low |
| TBLN/HIV coinfection-Ethiopia | 6 | 0.21 | 0.12–0.3 | 92.9 | low |
| TBLN/HIV co-infection-other African Countries | 8 | 0.73 | 0.61–0.85 | 95.3 | low |
| TBLN/HIV co-infection African overall | 14 | 0.52 | 0.33–0.71 | 99.2 | low |
| Exposure status | |||||
| New TBLN | 5 | 0.88 | 0.81–0.94 | 77.9 | low |
| Contact with Cougher | 7 | 0.33 | 0.24–0.41 | 84 | low |
| Livestock Exposure | 2 | 0.52 | 0.32–0.71 | 65.3 | low |
| History of eating raw meat/Drinking raw milk | 4 | 0.46 | 0.26–0.66 | 96.1 | low |
| BCG vaccination | 4 | 0.24 | 0.1–0.38 | 93.6 | low |
| Cardinal tuberculosis symptoms | |||||
| Fever | 7 | 0.45 | 0.19–0.71 | 98.9 | low |
| Night Sweating | 5 | 0.55 | 0.19–0.91 | 99.5 | low |
| Weight Loss | 7 | 0.62 | 0.46–0.78 | 97.5 | low |
| Cough >2 weeks | 6 | 0.32 | 0.25–0.39 | 78 | low |
HIV: Human immune deficiency syndrome; TBLN: Tuberculous Lymphadenitis; BCG: Bacille of Calmitte and Guerin; PP: pooled prevalence, CI: Confidence interval; QoE: Quality of Evidence